At present, MGT-based blood group test card has been used extensively in the field of blood typing, and MGT boasts of easy operation, high sensitivity, accurate results that can be saved and other strengthens, which allowed it to become method recommended by American Association of Blood Banks (AABB), technique recognized by FDA and internationally recognized blood group analysis test technique.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

According to network data analysis, market size of China’s blood grouping analyzer was RMB 1.704 billion in 2024, and it is predicted to achieve RMB 1.89 billion in 2025.

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monitoring solution for viral‑mediated cancers. The transaction is an extension of CareDx’s strategy to focus on its U.S. Precision Medicine Testing Services and Patient and Digital Solutions. The definitive agreement provides for an up-front cash consideration of $160 million with up to an additional $100 million based on the achievement of revenue milestones.

Laguna Diagnostics, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company's mRNA Gene Biomarker Test, a novel blood-based test designed to aid in the differentiation of schizophrenia and bipolar I disorder in symptomatic patients.

Integrated pipeline: high speed and high throughput instrument’s rigid demand of high-end hospitals and laboratories will develop towards the direction of integrated pipeline to meet high-end hospitals’ test requirements.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.

Several leading In Vitro Diagnostic (IVD) companies have posted their first-quarter results for 2026, showing mixed performance across revenue, profitability, and cash flow.

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026.

Rapigen, Inc., an in vitro diagnostics company specializing in rapid diagnostic tests, announced that three of its malaria rapid diagnostic tests (RDTs) — BIOCREDIT Malaria Ag Pf (pLDH), BIOCREDIT Malaria Ag Pf (pLDH/HRPII), and BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH) — were officially added to the World Health Organization (WHO) Prequalification (PQ) product list on April 14, 2025. With this listing, Rapigen becomes eligible for UN procurement channels and global public health supply programs.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.